Blog

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…

CertaraMarch 24, 2026

Guide

From Numbers to Narrative: Mastering the Art of PK Presentation

Master PK data reporting with a structured guide to presenting pharmacokinetic results clearly and turning…

CertaraMarch 20, 2026

Guide

Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer

Download Certara’s expert guide on pharmacometrics and pediatric drug development. Learn how modeling, MIDD, and…

CertaraMarch 19, 2026

Blog

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…

CertaraMarch 11, 2026

Webinar

What is new in Phoenix 8.8?

Danielle PillsburyMarch 9, 2026

Webinar

Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers

CertaraMarch 9, 2026

Guide

Navigate GxP Compliance in the Cloud with Confidence

Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…

CertaraMarch 6, 2026

Blog

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

CertaraMarch 3, 2026

Conference

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

Danielle PillsburyMarch 2, 2026

Live Events

Phoenix Roadshow 2026 – Cambridge

CertaraMarch 2, 2026

Clinical Pharmacology

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

From Numbers to Narrative: Mastering the Art of PK Presentation

Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

What is new in Phoenix 8.8?

Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers

Navigate GxP Compliance in the Cloud with Confidence

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

Phoenix Roadshow 2026 – Cambridge

Newsletter sign up

Quick links

Solutions

Contact